110 related articles for article (PubMed ID: 20635652)
21. Preparation and evaluation of a CD13/APN-targeting and hydrolase-resistant conjugate that comprises pingyangmycin and NGR motif-integrated apoprotein.
Li B; Zheng YB; Li DD; Zhen YS
J Pharm Sci; 2014 Apr; 103(4):1204-13. PubMed ID: 24504597
[TBL] [Abstract][Full Text] [Related]
22. [Cytotoxicity of chymopapain combined with pingyangmycin on mouse hepatoma cell line hepa-6].
Xiaoling C; Jie W; Yong G; Taicheng Y; Jiang X
Zhong Yao Cai; 2004 Apr; 27(4):267-9. PubMed ID: 15307684
[TBL] [Abstract][Full Text] [Related]
23. Chitosan-based liposomal thermogels for the controlled delivery of pingyangmycin: design, optimization and in vitro and in vivo studies.
Zhang L; Chen F; Zheng J; Wang H; Qin X; Pan W
Drug Deliv; 2018 Nov; 25(1):690-702. PubMed ID: 29484910
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of pingyangmycin-induced apoptosis of cultured human umbilical vein endothelial cells.
Huang YD; Tong X; Chen Q; Xia SW; Zhuo Y; Kang ZH; Xue XY
Genet Mol Res; 2017 May; 16(2):. PubMed ID: 28510249
[TBL] [Abstract][Full Text] [Related]
25. Pingyangmycin as a 99mTc carrier in tumor localization.
Huang T; Zhang Y; Wang J; Huang J; Liu D; Mong S
Nucl Med Biol; 1995 May; 22(4):537-42. PubMed ID: 7550032
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effects of monoclonal antibody Fab' fragment-containing immunoconjugates.
Liu X; Zhen Y
Chin Med Sci J; 2002 Mar; 17(1):1-6. PubMed ID: 12894876
[TBL] [Abstract][Full Text] [Related]
27. [Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma].
Chen WT; Guo W; Xu Q; Pan HY; Ye DX; Qiu WL
Zhonghua Kou Qiang Yi Xue Za Zhi; 2004 May; 39(3):218-20. PubMed ID: 15196390
[TBL] [Abstract][Full Text] [Related]
28. Percutaneous Treatment of Large Venous Malformations in the Oral and Maxillofacial Regions Using Electrochemical Therapy Combined With Pingyangmycin.
Xue L; Cao RY; Xu DP; Sun NN; Tan HS; Wang XK
J Oral Maxillofac Surg; 2015 Jul; 73(7):1384-91. PubMed ID: 25913514
[TBL] [Abstract][Full Text] [Related]
29. [Configuration in solution and activity mechanism studies on the anticancer Fe(II)-pingyangmycin (PYM) complex].
Jiang J; Guo Y; Zhou X
Yao Xue Xue Bao; 1998 Oct; 33(10):785-8. PubMed ID: 12016934
[TBL] [Abstract][Full Text] [Related]
30. [Inhibition of the growth of hepatoma and hepatic metastasis by pingyangmycin conjugated with Fab' fragment of monoclonal antibody].
Liu X; Shang B; Liu X
Zhonghua Yi Xue Za Zhi; 2001 Feb; 81(4):201-4. PubMed ID: 11798873
[TBL] [Abstract][Full Text] [Related]
31. [Effects of pingyangmycin on the growth and differentiation of the transplantable squamous cell carcinoma of forestomach (GS-742) in mice].
Wang FR
Zhonghua Zhong Liu Za Zhi; 1989 Sep; 11(5):326-8. PubMed ID: 2482804
[TBL] [Abstract][Full Text] [Related]
32. Application of microdialysis to study the in vivo release of pingyangmycin from in situ gels in rabbits.
Gao ZB; Ding PT; Zhang L; Yuan ZT; Shi J; Wei J; Chen DW
Biomed Chromatogr; 2006 Nov; 20(11):1223-8. PubMed ID: 16799932
[TBL] [Abstract][Full Text] [Related]
33. Study of a pingyangmycin delivery system: Zein/Zein-SAIB in situ gels.
Gao Z; Ding P; Zhang L; Shi J; Yuan S; Wei J; Chen D
Int J Pharm; 2007 Jan; 328(1):57-64. PubMed ID: 16939703
[TBL] [Abstract][Full Text] [Related]
34. Pingyangmycin loaded bovine serum albumin microspheres for chemoembolization therapy--in vitro and in vivo studies.
Wang C; Liu J; Pan W; Wang X; Gao Q; Hou S
Int J Pharm; 2008 Mar; 351(1-2):219-26. PubMed ID: 18054185
[TBL] [Abstract][Full Text] [Related]
35. [Experimental study of combined target treatments using PYM-BAC5 and 131I-BAC5 to nasopharyngeal carcinoma].
Liang ZP; Liu CZ; Cheng JY; Xiao XB; Zhang CQ; Liang CS
Ai Zheng; 2003 Aug; 22(8):831-5. PubMed ID: 12917029
[TBL] [Abstract][Full Text] [Related]
36. [Embolization and degradation of arteries in vivo by pingyangmycin albumin microspheres].
Wang LL; Gao QH; Zheng GJ; Wang XY; Zhou L; Wang CM; Wen YM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):279-83. PubMed ID: 19462907
[TBL] [Abstract][Full Text] [Related]
37. [The effect of diethyl-dithiocarbamate on the distribution of pingyangmycin in vivo].
Huang J; Zhang Y; Zhang M
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):104-7. PubMed ID: 7544726
[TBL] [Abstract][Full Text] [Related]
38. Preparation and characterization of Pingyangmycin-loaded bovine serum albumin microspheres for embolization therapy.
Wang C; Liu J; Gao Q; Bi Y; Gan L; Wang X; Hou S
Int J Pharm; 2007 May; 336(2):361-6. PubMed ID: 17360133
[TBL] [Abstract][Full Text] [Related]
39. [Effects of pingyangmycin on mucous membrane of respiratory tract and its prevention].
Chen F; Lin SZ; Gong ZP
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Aug; 38(4):285-8. PubMed ID: 14743640
[TBL] [Abstract][Full Text] [Related]
40. [An experirmental study on the preparation and drug sustained release characteristics of Pingyangmycin Albumin Microspheres].
Gao QH; Zheng GJ; Wang CG; Zhou L; Wen YM; Wang CM; Hou SX
Hua Xi Kou Qiang Yi Xue Za Zhi; 2005 Feb; 23(1):69-71. PubMed ID: 15804028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
